Phase 2 Epilepsy Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed with a type of brain tumour called glioblastoma (located in the upper part of the brain), diagnosed according to the 2021 WHO brain tumour classification system
• People who are able to give their signed consent to take part
• People who are over 18 years of age
• People whose doctors have determined them suitable for the standard combination of chemotherapy and radiotherapy using a drug called temozolomide (a shortened, hypofractionated course of radiotherapy is not permitted)
• People who score 70 or above on a standard medical scale that measures ability to carry out daily activities (called the Karnofsky Performance Scale)
• People who are considered mentally able to understand their situation, including being aware of where they are, the time, and their circumstances
• People for whom a preserved sample of their tumour tissue is available for review by a central pathology team
• People whose blood tests show that their blood cell counts, liver, and kidney function are within acceptable ranges

Who may not be able to join:

• People who are scheduled to receive a shortened (hypofractionated) course of radiotherapy
• People who are currently pregnant or breastfeeding
• People who plan to become pregnant, or whose partner plans to become pregnant, during the course of the study
• People of childbearing potential who are not using, or not willing to use, a reliable form of contraception throughout the study (such as the pill, injections, implants, or an intrauterine device) — this does not apply to people who are surgically sterilised or have been post-menopausal for more than two years
• People with other serious ongoing medical conditions, such as kidney failure, liver problems, or significant heart disease
• People with a known or suspected history of not following medical instructions, or with drug or alcohol misuse issues
• People who may be unable to follow the study procedures, for example due to language barriers, psychological conditions, or dementia
• People who have taken part in another clinical trial involving an experimental drug within the 30 days before joining, or who are currently in another such trial
• People who have previously been enrolled in this same trial
• People who are members of the research team running this trial, or their family members or dependants
• People who have previously had radiotherapy to the brain, or any prior radiotherapy that might overlap with the planned treatment area
• People who have another active cancer that could interfere with the study treatment
• People whose heart tracing (ECG) shows an abnormality in a measurement called QTc that is greater than 450 milliseconds
• People for whom a contrast-enhanced brain MRI scan using a substance called Gadolinium is not safe or suitable
• People who have previously had an allergic or intolerance reaction to any of the drugs used in this study
• People who have had intolerance reactions to a group of medicines called sulfonamides or to salicylates (such as aspirin-related compounds)
• People with a condition called acute intermittent porphyria
• People with a known deficiency of an enzyme called glucose-6-phosphate dehydrogenase
• People currently taking any of the following medications: digoxin, cyclosporin, or methotrexate
• People with a history of serious skin or immune reactions to medications, including conditions known as exfoliative dermatitis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, DRESS syndrome, or renal tubular acidosis

Important: Always verify eligibility with the trial site directly before applying.